NCT02567435 2026-03-17
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
C. R. Bard
University of California, San Francisco
National Institutes of Health Clinical Center (CC)